Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Derrick Gingery

Senior Writer

Washington, DC
Senior writer Derrick Gingery has been reporting on regulatory issues for "The Pink Sheet" and "The Pink Sheet" Daily since 2010. Among his favorite topics are FDA's user fee programs, along with generic drug and biosimilar policy, but he also handles drug approval issues and general FDA news.

An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.

When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.

Latest From Derrick Gingery

Pfizer AdComm Asks Many Questions About COVID Vaccine For Ages 5-11, But Gets Few Answers

Often data was not available from FDA, CDC or the sponsor to answer subgroup, safety and other questions that could have influenced the outcome of the advisory committee meeting.

Advisory Committees Vaccines

Full US FDA Independent Review Of Janssen Booster Data May Not Continue Post-EUA

The agency said its booster EUA decision was based on the immunogenicity studies that were submitted.

Coronavirus COVID-19 Vaccines

Pfizer Push For COVID Vaccine EUA In Ages 5-11 Includes School, Mental Health Arguments

Briefing documents for the upcoming advisory committee tout potential ‘indirect’ benefits and argue that lower dose should address myocarditis concerns.

Advisory Committees Coronavirus COVID-19

Real-World Evidence: ‘Labor-Intensive’ Data Standardization May Be Required By US FDA

New draft guidance offers recommendations for translating real-world data from claims or EHR sources to meet FDA data requirements.

Real-World Evidence Clinical Trials

Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders

Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.

FDA Leadership

Janssen Gets US FDA Panel Nod For Additional COVID Vaccine Shot – But Is It A ‘Booster’?

Advisory committee members say clinical data proves the second shot should be considered part of the primary series, while Janssen wants it called a single-shot vaccine with a booster.

Vaccines Coronavirus COVID-19
See All
UsernamePublicRestriction

Register